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HyStem®: A Unique Clinical 
Grade Hydrogel for Present and 
Future Medical Applications
Thomas I. Zarembinski and Aleksander Skardal
Abstract
Medicine needs targeted, minimally-invasive delivery of protein-based and 
cell-based therapeutics to increase efficacy and reduce occurrence and severity of 
side effects. Local delivery requires a matrix to sequester and protect the medicine 
until its effect can be realized. The problem is, unlike stable small molecule drugs, 
proteins and cells cannot be co-packaged with a matrix in a prefilled syringe—they 
must be mixed with their matrix at the point of care. HyStem hydrogels fix this 
problem: They are arguably the first commercially available, GMP-qualified biode-
gradable hydrogels both with the ability to formulate with either proteins or cells 
in the hospital/surgical suite and with a history of safe use in humans. HyStem is 
designed to be protein, cell-friendly and in situ crosslinkable, permitting homo-
geneous mixing of therapeutics. One HyStem formulation is 510(k) cleared and 
another the subject of two European clinical trials. Key applications include local-
ized delivery of therapeutic growth factors, antibodies, and cells. In the future, we 
envision HyStem’s flexibility and clinical use history forming the basis for a new 
generation of therapeutics. Two examples described here include HyStem’s use for 
patient-derived organoid culture to develop new drugs as well as for bioprinting to 
manufacture new organs.
Keywords: HyStem, GMP, hyaluronic acid, extracellular matrix, delivery, organoid, 
bioprinting
1. Introduction
A hydrogel is a crosslinked, water-rich network that can be fabricated from a 
wide variety of hydrophilic, biological or bio-inspired polymers. Human beings are 
in fact largely hydrogel: cellular cytoplasm is a hydrogel as is the extracellular matrix 
that surrounds them [1, 2]. Many body substances are also hydrogels (e.g. mucus 
[3], blood clots [4]). It can be argued that hydrogels in the human body carry out 
many of their functions as a result of being water swollen and that the functional-
ity of manufactured hydrogels also relies heavily on this capability They can heal 
through hydrating and protecting wounded surfaces, fill empty spaces where there 
used to be tissue in younger days or prior to disease or injury, seal surgical wounds 
that cannot reintegrate on their own, and deliver therapeutics to places that can-
not easily be accessed from systemic routes. A variety of animal and plant-based 
hydrogels (e.g. gelatin, pectin, carrageenan) are also used in our food supply.
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Despite their restorative potential, relatively few hydrogels are currently mar-
keted for human medical use. This is because commercialization is neither cheap 
nor easy: product development demands years of effort to design a stable product 
that is user-friendly and cheap enough to sustain commercial requirements [5]; 
cGMP manufacture is expensive, especially if aseptic vial fill filling is required. 
Commercialization also requires the requisite quality system to support the cGMP 
manufacturing as required by FDA 21CFR820. The regulatory path can also be oner-
ous: while hydrogels are generally considered medical devices (Class II or III) by the 
US FDA, obtaining FDA approval in combination with therapeutics (drugs or cells) 
can increase the complexity and length of the regulatory journey due to the need for 
oversight by multiple FDA agencies [6].
A growing focus is in local administration of therapies to not only deliver disease-
modifying drugs but also to rebuild damaged tissues [7–9]. Given the arduous path to 
the clinic, it is tempting to short-circuit the normal manufacturing/quality/regula-
tory/clinical path by improvising by using marketed hydrogels approved for different 
indications and derived from commonly-used biological polymers (see Table 1). 
While this approach may be attractive in the short-term, there is little gained in the 
long term. This is because hydrogels must be re-optimized for each therapeutic. In 
addition, the regulatory and clinical paths will not be circumvented: these medical 
devices, like drugs, must be approved independently for each new indication [10–12].
If a short-term fix is required, what is the harm in selecting a hydrogel from 
Table 1 to locally deliver a therapeutic? Upon closer inspection, it becomes 
clear that a non-optimized hydrogel adds additional risk to the success of the 
therapeutic. HA-only hydrogels (Dermal Fillers, Viscosupplements, Opthalmic 
and Gynecology hydrogels), must be excluded for anchorage-dependent cells 
like mesenchymal stem cells (MSC)—they do not provide the requisite cellular 
attachment sequences required to prevent anoikis [13]. Many hydrogels (Dermal 
Fillers, Viscosupplements) are also pre-crosslinked within its sterile syringe and 
are dubbed monolithic [9], preventing homogeneous mixing with drugs or cells. 
Tissue sealants made from fibrin actually fulfill two key criteria: they contain 
fibronectin, an effective cellular attachment protein for many cell types [14]. 
They also form a gel after its components are combined, allowing homogeneous 
mixing of cells. These sealants however suffer from their lack of staying power: 
Class Example Key polymer Marketed state Cellular 
attachment 
sites present
Wound management Biozel®, 
Integra® Wound 
Matrix
Hyaluronic  
acid (HA), 
collagen
Uncrosslinked Yes
Tissue sealants Evicel®, 
Tisseel®
Fibrin Uncrosslinked Yes
Dermal fillers Juvederm®, 
Restylane®
HA Crosslinked No
Viscosupplements Synvisc®, 
Hyalgan®
HA Crosslinked No
Opthalmic Healon®, 
Provisc®
HA Uncrosslinked No
Gynecology HyaloGyn® HA Uncrosslinked No
Table 1. 
A sample of currently marketed hydrogels.
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the endogenous plasmin degrades the hydrogel within a week, providing only 
brief shelter for the therapeutic [15]. Fibrin is also difficult to use for indica-
tions outside of tissue sealing. This is because it is formulated to gel in 3–5 min 
[16], placing a short and rigid timeframe for mixing with other therapeutics and 
injecting in the operating room. Collagen-containing matrices (wound manage-
ment) have collagen which provides requisite cellular attachment sites [15]. The 
challenge with some wound management devices (e.g. Integra flowable wound 
matrix, Table 1) is that the collagen can be granulated. These insoluble collagen 
particles will not homogeneously mix with its matrix, providing suboptimal cel-
lular attachment. Many also do not form covalent crosslinks, deteriorating their 
staying power [15].
What is needed is a biodegradable, biocompatible hydrogel platform that is 
not only customizable but also provides the requisite foundation for streamlined 
regulatory approval. The HyStem hydrogel platform, a clinical grade customiz-
able hydrogel matrix, fulfills these criteria. While a discussion of key aspects to 
hydrogel selection and commercialization was described previously [17], this 
review serves to pick up where it has left off. This book chapter will have three 
parts: First, an introduction to the history and basics of the technology; Second, 
a description of the successful uses of the HyStem platform based on our cus-
tomers and collaborators’ published experiences for the past 10 years for both 
drug and cell delivery. Third, an introduction and description to recent studies 
in what we believe will provide the springboard to future therapies: HyStem’s use 
for preparing tissue-specific and patient-derived organoid culture to develop 
new drugs as well as HyStem’s use as a bioink for bioprinting to manufacture 
new organs.
2. Background
2.1 History
The HyStem technology was developed in the laboratory of Dr. Glenn 
Prestwich in the Department of Medicinal Chemistry at the University of Utah. 
The goal was to develop a hydrogel platform designed to recapitulate the minimal 
composition necessary to obtain a functional extracellular matrix [ECM] while 
using specific design criteria for both function and future commercialization [9]. 
Since the first publication in 2002 [18], over 200 articles have been published 
describing novel uses of the technology for drug and cell delivery. Glycosan 
BioSystems (Salt Lake City, Utah) obtained the exclusive rights to the technology 
to certain fields of use for medical and research applications in 2006. Glycosan 
commercialized the technology in late 2006 for research use with the ultimate 
goal of manufacturing and providing clinical grade material to a growing cell 
therapy market. BioTime (Alameda, CA) acquired glycosan in 2011, manu-
factured cGMP-qualified HyStem, and subsequently performed the requisite 
ISO-10993 biocompatibility experiments and stability experiments in support 
of regulatory clearances and approvals. In 2014, one HyStem formulation was 
510(k)-cleared for wound management (tradename Premvia™; 510(k) number: 
K134037). In 2013, BioTime also embarked on two European clinical studies using 
another HyStem formulation (tradename Renevia®) as a delivery vehicle for 
autologous fat-derived cells to treat HIV-associated facial lipoatrophy (HIVLA). 
BioTime successfully completed its pivotal clinical study in 2017 and met its 
primary clinical endpoints.
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2.2 Composition and reaction mechanism
The elegance of the HyStem platform is in its three building blocks. They cova-
lently bind to each other like Lego® blocks and they can be used to make highly 
customized and complex matrices: these blocks are called Glycosil®, Gelin®, and 
Extralink® (Figure 1). Each has a specific role in the platform (Table 2). The most 
basic form of the platform is called HyStem-C where the concentration (w/v) ratios 
of Glycosil:Gelin:Extralink are equal in concentration (w/v) (Table 2 and Figure 2). 
Upon mixing, Extralink’s acrylates react with the former two components’ thiol groups 
via click chemistry (Michael addition reaction) [13, 19]. Crosslinks form in trans (e.g. 
Glycosil molecules can link to Gelin as well as to neighboring Glycosil molecules). In 
addition, given Glycosil’s large molecular weight and its ability to adopt semiflexible 
random coil configurations, it can likely loop back on itself and bind in cis (Figure 3) 
[20]. The final clear, transparent, viscoelastic hydrogel forms at physiologic pH and 
temperature in approximately 20 min and is greater than 98% water. This time frame 
allows an investigator to both customize the hydrogel with drugs or cells and to load 
and deliver the mixture through a cannula.
Also like Lego® blocks, these three base blocks can be used to make highly 
customized and complex matrices in large part due to its thiol chemistry. First, 
the number of blocks can be changed. For example, the addition of thiolated or 
thiol-reactive species allows a user to fundamentally change the character of the 
matrix. One case is the addition of thiolated heparin which provides a negatively 
charged component crosslinked into the matrix. This added character can aid in 
significantly increased sustained release of proteins non-covalently incorporated 
into the matrix prior to gelation [21, 22]. The marketed version of this mixture is 
called HyStem-HP (Table 3). In addition, the incorporation of either acrylate or 
maleimide-tagged molecules allows facile covalent linkage directly to the thiolated 
species [23–25]. Sometimes, however, less is more: removal of the Gelin component 
from HyStem-C provides an in situ crosslinkable adhesion barrier [26] (Table 3).
Second, the levels of each component can be adjusted to change the hydrogel 
properties. HyStem is a soft gel and can be tailored to stiffnesses comparable to tis-
sues such as endoderm, nerve, liver, and smooth muscle (G’ 20–3500 Pa) (Table 3).  
[17, 27, 28]. In more basic terms, HyStem can be made to be as soft of flavored gelatin 
(G’ 35 Pa) or moderately stiffer than Greek yogurt (G’ 1900 Pa) (B. Lohman and 
T. Zarembinski, unpublished). Its stiffness is modulated primarily by increasing 
Glycosil and/or Extralink concentrations [28]. Its pore size (less than 15.9 nm based 
on the hydrodynamic radius of trapped polymers (Table 3)) can also be modulated 
Figure 1. 
HyStem-C building blocks. Shapes are as follows: unfilled circles, oxygen; blue circles, nitrogen; yellow partial 
circles, sulfur; red triangle, acrylate.
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Glycosil Gelin Extralink References
Identity Thiol-
modified 
hyaluronate
Thiol-modified 
porcine gelatin
Polyethylene 
glycol diacrylate
[18, 19, 85]
Purpose Backbone of 
gel
Cellular 
attachment sites
Crosslinker [18, 19, 85]
Substitution density 30% of HA 
repeating units
42% of available 
carboxylates
>65% 
bis-acrylation
[85]
Mw (kDa) 160 Heterogeneous 3.4 [19]
Final concentrations 
in gel (mg/ml)
4 4 4 Unpublished
Table 2. 
HyStem-C component characteristics.
Figure 2. 
Glycosil and Gelin prior to gelation. Shapes are as same as those for Figure 1.
Figure 3. 
Covalent bonding in HyStem after gelation upon addition of Extralink. Shapes are same as for Figure 1 with 
addition of purple circles (new bond resulting from Michael addition reaction).
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from by increasing or decreasing the density of crosslinks of the HyStem-C hydrogel 
[29, 30]. Third, HyStem composition can be easily altered by adding in any compo-
nent (e.g. drug, protein) by incorporating it prior to full gelation. This is possible 
since HyStem has a medium rate of gelation (10–20 min) compared to other in situ 
crosslinking hydrogels [17] (Table 3). This non-covalent addition of any therapeutic 
cargo paves the way for drug and cell delivery to be discussed next.
3. Drug delivery
Sustained release of drugs of both small molecules and protein drugs occurs 
when they are incorporated into HyStem. While a compilation of drug release 
results and conclusions for individual HyStem formulations is presented below, 
this is not the point. The key is HyStem’s flexibility: it can be leveraged to adjust 
release. This modulation can be done by either changing its crosslinking density by 
increased Extralink or Glycosil concentrations or by including different polymers 
with affinity for the drug such as heparin [21] or increased Gelin (M. Onorato, 
unpublished). In the end, this ability to optimize formulation can be crucial for 
maximizing efficacy in vivo [31].
HyStem utility for drug delivery was first described in 2005 with the sustained 
release of human serum albumin (HSA, 66 kDa) and human basic fibroblast growth 
factor (bFGF, 16 kDa) from the prototype to the HyStem-HP product (containing 
thiolated heparin crosslinked into the matrix). bFGF was released over 35 days 
at different velocities depending on amount of thiolated HP present [21]. This 
publication was important not only because it was the first illustration of HyStem’s 
capabilities in drug delivery but it underscores the complexity of drug release: sev-
eral variables affect speed and extent of release. These include identity of protein, 
molecular weight, base gel polymer (hyaluronic acid (uncharged) or chondroitin 
sulfate), presence of hyaluronidase (HAse), and release solution composition [21]. 
Sustained drug release can also occur by using HyStem to immobilize MSC engi-
neered to express and secrete therapeutics like diabodies [32] or by covalent linkage 
of a small molecule to HyStem to further slow its release [33].
Generally, drugs release from hydrogels is diffusion-driven [34]. HyStem 
hydrogels are no different in vitro: they typically display first order release directly 
proportional to the drug concentration in the hydrogel [8]. There are two excep-
tions: Celecoxib and BMP-2 which display near zero order release independent of 
concentration [8, 31]. Celecoxib is poorly water soluble and the possibility exists 
that molecule may have precipitated or crystallized in gel [35]. In this event, the 
molecule’s release may be dependent gradual disintegration of the solid [36]. Slow 
Attribute References
Appearance Clear [19]
Gelation time Approx. 10–20 min [19]
Versions 1. HyStem-C (Glycosil, Gelin, Extralink)
2. HyStem-HP (Glycosil with thiolated heparin, Gelin, 
Extralink)
3. HyStem (Glycosil, Extralink)
[9]
Stiffness (G’ Pa) 20–3500 [28]
Pore size (nm) < 15.9 [29]
Table 3. 
Final hydrogel characteristics.
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release of BMP-2 has been described before from HA-based hydrogels and the 
mechanism for its release is unclear [37].
Another general rule is the smaller the molecule, the faster the release. Small 
organic molecules less than 1 kDa are usually fully released from hydrogel after 6 hours 
and larger proteins like antibodies are released on the order of days (Tables 4 and 5; 
Figure 4), compare data points on left and right of vertical dotted line. Red data point 
1 (dexamethasone) and blue data point 3 (Celecoxib) are outliers for reasons described 
in this section). The relationship is not linear; this is particularly true of proteins 
whose release from HyStem hydrogels shows little correlation between molecular 
weight and release time (Figure 4, right of vertical dotted line). This result suggests 
that their different shapes and surface charges may affect rate of release. There is also a 
difference in release depending on whether it is measured in vitro or in vivo; Proteins in 
vivo release rate tend to have slower release rates (Figure 4, blue compared to red data 
points). This increase could be due to the increased resistance to release in the protein-
rich host fluids and tissue. In the end, the optimal release rate for in vivo efficacy 
must be empirically determined since it is difficult to predict. For example, BMP-2 
is released faster in HyStem compared to HyStem-HP, leading to a more complete 
release for HyStem at day 28 (84%) compared to the latter (68% for HyStem-HP). 
Drug Matrix Release 
time 
(days)
MW 
(kDa)
Final 
concentration 
(mg/ml)
Area of 
research
Reference
1. 
Lenalidomide
HyStem 0.25 0.26 1.33 Cancer [8]
2. R848 HyStem 0.25 0.31 1.33 Cancer [8]
3. Celecoxib HyStem 18 0.38 10 Cancer [8]
4. 2′3’-cGAMP HyStem 0.25 0.67 0.67 Cancer [8]
5. BMP-2 HyStem or 
HyStem-HP 
(no Gelin)
28 26 0.17 Orthopedic [31]
6. IL-15sa HyStem 2 29 0.06 Cancer [8]
7. Anti-PD1 HyStem 5 150 2 Cancer [8]
Table 4. 
Listing of drugs released from HyStem hydrogels (in vitro).
Drug Matrix Release 
time 
(days)
MW 
(kDa)
Final 
concentration 
(mg/ml)
Area of 
research
Reference
1. Dexamethasone HyStem-C* 3 0.39 10 Auricular [86]
2. IGF-1 HyStem-HP 28 7.6 0.02 Stroke [87]
3. BDNF HyStem-C 21 27 0.1–0.17 Stroke [88, 89]
4. TrkB-Fc HyStem-HP 5 125 0.005 Stroke [88]
5. Ascorbic acid and 
platelet-rich plasma
HyStem-HP n/a Multiple 0.05 (ascorbic 
acid)
Myocardial 
infarction
[90]
6. miR-29B HyStem n/a 7.5 1.0 Myocardial 
infarction
[41]
*A version of HyStem-C that was used with four-fold lowered Gelin concentration.
Table 5. 
Listing of drugs released from HyStem hydrogels (in vivo).
Hydrogels - Smart Materials for Biomedical Applications
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Unexpectedly, faster release corresponds to better efficacy since the former yields 50% 
more ectopic bone formation [31].
In addition to small molecules and proteins, future opportunities for HyStem 
will be for the sustained release of a new class of polymer therapeutics, nucleic 
acids. In 2016, 69 antisense oligonucleotides and 37 siRNAs were in clinical trials 
[38]. These numbers have grown in 2018 to 87 and 57 trials, respectively (search 
terms: antisense oligonucleotides and siRNA in clinicaltrials.gov). HyStem can 
add value especially by protecting the nucleic acids from the host immune system 
[39]. So far, delivery of the agomir version of miR-26A and of miR-29B have been 
reported [40, 41]; in addition, double-stranded phosphorothioated DNA oligo-
nucleotides have also been released slowly over 7 days at 10 mg/ml and higher; this 
rate of release can be modulated by adjusting the levels of Gelin in the final HyStem 
hydrogel (M. Onorato, unpublished).
4. Cell delivery
HyStem is a versatile tool for the implantation of cells. Beyond the ease of use 
mentioned previously, the biomaterial constituents provide two key functions that 
can be used to improve cell-based therapies. First, because these biopolymers are 
normally found in ECM and can be easily remodeled [19], HyStem can provide a 
more habitable environment for implanted cells and thereby improve engraftment. 
Second, HyStem’s base biopolymers, hyaluronan and collagen, are ubiquitously 
found in tissues and the implant composition and structure is not considered for-
eign. This characteristic plus the small pore size of the hydrogel excluding host cells 
allows HyStem to shroud the implanted cells from the host’s immune system while 
providing cellular attachment sites [29, 42]. Both of these aspects used together, 
provides a versatile and tailorable platform for implantation of cells into many tis-
sues for a variety of indications. The combination of these attributes likely explains 
HyStem’s ability to support cell survival post-implantation and to ultimately 
provide better in vivo efficacy in rodent models (Table 6) [43, 44].
Herein, HyStem will be presented in two different contexts for cellular delivery. 
(1) HyStem as a synthetic ECM for cellular remodeling and tissue regeneration 
Figure 4. 
Release rate of different sized molecules from HyStem hydrogels. Numbered, blue dots refer to in vitro molecules 
listed in Table 4; numbered, red dots refer to in vivo released drugs in Table 5). Blue dotted vertical line 
separates low molecular weight small molecules (left) from proteins.
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(e.g. implantation and remodeling into native tissues) and (2) HyStem as an 
encapsulating matrix to maintain cellular fitness, localization, and isolation (e.g. 
paracrine effects of implanted cell and/or immuno-isolation of implanted cells).
The first publication describing the utility of HyStem hydrogel for cell delivery 
appeared in 2004 [19]. Hydrogels seeded with T31 human tracheal scar fibroblasts 
implanted in nude mice showed two important milestones 8 weeks post-implanta-
tion: the cells were proliferating and also producing their own extracellular matrix. 
By these measures, the cells had made a home for themselves and were going about 
populating the space provided by the hydrogel. This work has since been extended to 
a variety of cell types such as cardiac, neural, mesenchymal based cells [32, 43–45].
While most animal experiments so far reported were performed for several 
weeks to show improvement in in vivo function across a variety of indications 
(Table 6), the possibility exists that this improved efficacy can further be ampli-
fied with lengthened time points. One case in point is the transplantation of 
pancreatic islets in diabetic rats using HyStem-C [29]. Surprisingly, the diabetic 
rats maintained normal glucose levels and remained insulin-independent for at 
least 80 weeks (1.5 years) and may have been studied over still longer term had 
the animals not succumbed to old-age related diseases. The longevity of cellular 
response is attributed at least in part to reduce fibrosis which is well known to occur 
in the alginate-based biomaterials more popular for this application.
Successful use of HyStem in animals portended successful use in humans. A 
major challenge in HIV patients is the disappearance of facial fat resulting from 
highly active antiretroviral therapy (HAART) and is known as HIV-associated 
lipoatrophy [46, 47]. One approach to treat this HAART complication is to 
transplant a patient’s own fat-derived cells (stromal vascular fraction cells, SVF) 
Cell type Matrix Last 
data 
point 
(days)
Area of research Reference
Endothelial progenitor cells HyStem-C 14 Nephrology [42]
Neural progenitor cells HyStem-HP 14 Stroke [45]
Placenta-derived adherent cell HyStem-C 56 Orthopedic [91]
NSC and MSC expressing 
sTrail
HyStem-C 28 Glioblastoma [44]
Cardiosphere-derived cells HyStem-C 1 Myocardial 
infarction
[43]
Neural stem cells HyStem-C 14 Imaging [92]
Retinal progenitor cells HyStem-C and 
variations thereof
7 Ophthalmic [93]
MSC expressing oHSV HyStem-C 12 Glioblastoma [94]
NSC expressing Pseudomonas 
exotoxin
HyStem-C 21 Glioblastoma [95]
MSC/GDF5 (growth 
differentiation factor 5)
HyStem-C 42 Bone formation 
(dental)
[96]
Islet beta-cells HyStem-C 560 Diabetes [29]
Cardiomyocytes HyStem-C 28 Myocardial 
infarction
[97]
Table 6. 
Listing of cells delivered in HyStem hydrogels (in vivo).
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subcutaneously in the facial deficits. A clinical version of HyStem, Renevia, was used 
to deliver these cells harvested by liposuction and reinjected subcutaneously. The 
pivotal trial was a European, multi-center, randomized, evaluator-blinded, delayed-
treatment-controlled study of the effectiveness and safety of Renevia in combina-
tion with the autologous SVF. The primary endpoint in this 56 patient trial was the 
change in hemifacial volume at 6 months in treated patients compared to patients in 
the delayed treatment arm as measured by 3D photographic volumetric assessment. 
Renevia successfully met the primary endpoint with treated patients retaining 100% 
of transplanted volume at 6 months. In addition, treated patients retained 70% 
and 64% of the transplanted volume at 12 and 18 months, respectively. All Renevia 
transplants were shown to be well tolerated and there were no device-related serious 
adverse events noted during this trial (investor.biotimeinc.com).
5. Future technologies
5.1 Introduction to organoids
In the current drug development pipeline, preclinical testing of novel drug 
compounds in 2D cell cultures is well established, but is not always accurately 
predictive of clinical outcomes in human subjects. [48]. This result is not surprising 
since cells grown in 2D using plastic dishes experience drastically different surface 
topography, mechanical properties, cell–cell interactions, cell-matrix interactions, 
and nutrient diffusion properties compared to a 3D architecture.
Organoids (also called organ-specific 3D cultures) are three-dimensional 
constructs comprised of tissue-specific cells with the intention of recapitulating 
the cellular microenvironment and function of their originating tissues. While 
organoids can be formed through self-aggregation to form spheroids, they are also 
formed using biomaterial hydrogels that suspend cells in 3D within polymer or 
protein-networked matrices (refer to the different methods shown in Figure 5).  
Biomaterial-based approaches have an advantage used over spheroid-based 
approaches as they allow for heightened control of the organoid and organoid 
microenvironment composition with regard to cellular, biochemical, and physical 
parameters, such as stiffness, addition of ECM components, and spatial organiza-
tion of cell types [49, 50]. Organoids often contain multiple cell types that are 
representative of those typically found within their target tissues [51]. Importantly, 
these differences result in significant phenotypic and gene expression changes that 
is much more reflective of their in vivo origin. For example, when grown metastatic 
colon carcinoma cells are cultured in 2D culture, they exhibit an epithelial mor-
phology and expression profile. In contrast, when the cells are introduced into a 
3D liver organoid environment supported by HyStem, they “switched” to adopt a 
mesenchymal and metastatic phenotype [52, 53].
5.2 Novel platforms for making and using organoids
HyStem has been employed to create a wide variety of 3D tissue constructs and 
organoid form factors since its composition and gelation time can be customized for 
each model. An example of composition customization is in a recently-developed 
liver model: primary human hepatocyte spheroids are embedded into HyStem 
hydrogels modified to include liver-specific ECM extract [54]. The inclusion of 
liver ECM increases long-term hepatocyte viability, stabilizes albumin secretion, 
and supports cytochrome p450 activity [55]. These organoids have been tested in 
environmental toxin screening [56], and are currently being used to screen a range 
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of previously recalled drugs as further validation. This model can also be integrated 
into multi-tissue organoid, body-on-a-chip systems to test drug or toxin kinetics 
in the context of multiple organs [54, 57]. Lastly, organoids can also be formed by 
bioprinting technologies (discussed below).
Customization of HyStem’s gelation time also enables novel approaches to gen-
erating and using organoids. Two examples include using bioprinting technologies 
(Figure 5E) to be discussed in the next section) and organ-on-a-chip technology. 
Organ-on-a-chip is a nascent 3D-based technology which employs microfluidics to 
more accurately model in vivo tissues by simulating its hydrodynamic flow as well 
as its placement of multiple cell types in close proximity with respect to one another 
[58]. This technology can also be used to make organoids by customizing HyStem’s 
crosslinking for spatio-temporal control of gelation. For example, the recent creation 
of in vitro cancer models employ a range of biofabrication approaches, all which 
employ HyStem in a variety of methods. Since many tissue- and tumor-on-a-chip 
Figure 5. 
Organoid biofabrication methods and form factors. (A) Examples of microfluidic devices that house organoids 
that are (B) photopatterned in situ through hydrogel precursor exposure within the devices through photomasks 
to UV or blue light, initiating crosslinking. (C) Rotating wall vessel bioreactor culture of (D) tumor organoids. 
(E) Extrusion bioprinting of cell-laden laden hydrogel bioinks.
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platforms are based on closed microfluidic devices with no direct access to locations 
in which tissues will reside, introduction of cells is performed generally through 
fluid flow channels. To introduce 3D tissue and tumor constructs within such sealed 
microfluidic devices (Figure 5A) 3D hydrogel photopatterning strategies were 
developed. By adding light activated photoinitiator molecules (e.g. Irgacure 2959), 
HyStem is able to form solid structures by shining light through photomasks to 
yield defined shapes and locations in situ within microfluidic devices (Figure 5B) 
[59]. By harnessing control over the extracellular matrix components and adding 
healthy cells, the resulting organoids can have more complex stroma and extracel-
lular matrix architectures, which provide additional components that contribute 
to overall tissue-tumor physiology [60]. Additional complexity can be realized by 
creating multiple tissue and tumor organoids and combining them in a single closed 
system. This facilitates study of phenomena such as metastasis, where events take 
place in two locations—a primary tumor site and a downstream site of metastasis. 
We recently demonstrated a metastasis-on-a-chip platform to model metastasis of 
colorectal cancer cells from a gut organoid to a liver organoid [53]. We have been able 
to encapsulate dissociated tumor populations from these biospecimens in 3D using 
HyStem or its derivatives, forming patient-derived tumor organoids for precision 
medicine applications for patient specific diagnosis and treatment [61, 62].
5.3 Bioprinting
The shortage of donor organs for implantation in patients has been a significant 
problem for years, [63, 64] and does not appear to be improving quickly [65]. 
For example, as of July of 2017, over 117,000 patients were still on waiting lists 
for donor organs, and there are only 8096 currently identified available donors 
[66]. Bioengineered tissues and organs have the potential to address this need for 
implantable tissues for patients waiting on donor lists. Bioprinting technologies 
have advanced in recent years, holding immense potential to 1 day be employed for 
biomanufacturing of transplantable tissues and widely adopted human testbeds.
Bioprinting is a multi-disciplinary technology that has emerged in recent years 
as a tool with immense potential in regenerative medicine and tissue engineering 
that combines 3D printing, biomaterials, and cell biology. [67–70] Bioprinting is 
a relatively new field within biotechnology and biomedical research (less than 2 
decades old) that can be described as robotic additive biofabrication with a goal to 
create viable and functional 3D organ or tissue structures [71–75]. A number of bio-
printing approaches have been recently explored, encompassing use of inkjet-like 
printers, extrusion devices, and laser-assisted devices [72, 73, 76]. Biomaterials play 
an integral role in bioprinting, as they act as the “glue”, figuratively and literally, 
that connect the fabrication approaches with the biological components [72, 73]. 
Currently, few biomaterials exist that both integrate seamlessly with bioprinting 
hardware and are optimally compatible with living cells. Most biomaterials used in 
bioprinting employ terminal covalent or physical bond formation during sol–gel 
transitions, requiring precise timing or control over chemical reactions to facilitate 
printing. Put simply, if one bioprints too soon, the result is a puddle of the bioink 
material and cells; if one bioprints too late, the bioink is too stiff and clogs the 
printer. Being able to control this transition to enable successful printing of 3D 
structures has been a major focus in bioink development.
HyStem and its individual components have played important roles in the develop-
ment of bioinks for bioprinting since the early days of bioprinting, where our group 
published several of the first studies in which novel biomaterial bioinks were devel-
oped specifically for 3D bioprinting [77, 78]. The key is in its compatibility with the 
bioprinting process. More specifically, the same characteristics that enable organoid 
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culture apply here to bioprinting: HyStem can be customized easily while providing 
a cell-friendly matrix. For example, HyStem forms very soft hydrogels that are not 
structurally robust, and the crosslinking methods employed do not facilitate effective 
extrusion bioprinting. This result can be a limitation in terms of scalability. To address 
these problems, new crosslinking and molding techniques were developed which 
increase the breadth of the bioprints formed (Table 7). These technologies include 
the ability to form supporting matrix allowing the printing of fragile structures and 
which can be removed (gold nanoparticles, AuNPs). The use of multi-armed PEG 
Crosslinker/crosslinking strategy Key attributes
Gold nanoparticles 1. Slow gelling (24–96 hours)
2. Reversible
Four-armed PEG acrylate Stiffer gels
Addition of photoinitiator Rapid crosslinking using light initiation
Addition of tetraorthosilicate Thixotropic quality
Table 7. 
Different crosslinking chemistries with HyStem for bioprintin.
Figure 6. 
Description of a multi-step crosslinking, HyStem-based hydrogel bioink. (A) Controlling G’ and G” using a 
multi-crosslinking approach to facilitate extrusion bioprinting of thiolated HA and gelatin-based hydrogels 
through thiol-acrylate and thiol-alkyne reactions. (B) Data from rheological testing of bioink formulations, 
demonstrating the capability to mimic the elastic modulus of many soft tissues in the body. (C) Tissues occupy 
different ranges of elastic moduli.
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Figure 7. 
Thixotropic HA hydrogels. (A) Hyaluronic acid and gelatin thixotropic hydrogel, formed using complexing 
with tetraorthosilicate (TEOS). (B) A depiction of a thixotropic loop mechanical test and (C) the HA-gelatin 
thixotropic hydrogel under such a test, indicating thixotropic characteristics. (D) A stress sweep and recovery 
demonstrating thixotropy.
acrylate crosslinkers to stiffen the gel [78, 79]; multistep spontaneous and light-
initiated crosslinking to spatio-temporally regulate crosslinking (Figure 6, Table 7 
[80, 81]); and inclusion of tetraorthosilicate to render HyStem thixotropic (allowing 
extrusion due to reversible liquefaction of the hydrogel (Figure 7)).
6. Conclusion
In summary, HyStem’s strength is in its clinical roots, its protein and cell compat-
ibility, and its flexibility to enable optimized drug and cell delivery. These attributes 
make HyStem well-suited for present applications such as local delivery of protein 
and autologous cells as well as future applications are also such as organoid culture 
for better drug discovery and development as well as bioprinting of tissue and 
organs. in the longer term, we envision HyStem to be a platform for using these new 
technologies to develop the next generation of made-to-order therapies and tissues 
for an increasing tissue and organ starved human community, whether it be an 
individual requiring an organ transplant due to disease, a tissue transplant due to 
injury, or the multiple needs of the wounded warrior.
We also envision HyStem eventually becoming a standard building block for a 
wide variety of future therapies so that it is clinically available for a physician as an 
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off-the-shelf, general delivery vehicle. This is because new technologies based on 
20–100 nm nanoparticles for drug delivery and for theranostics will require a deliv-
ery vehicle for local and/or sustained delivery [82, 83]. In addition, local cellular 
delivery of nucleic acids will grow in need especially with the rapid development of 
CRISPR/Cas9 technology for delivery to specific organs and tissues [84].
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